ChemInform Abstract: RAMAN SPECTRUM OF PHASE III OF SOLID METHANE IN THE LATTICE AND INTRAMOLECULAR REGIONS

1979 ◽  
Vol 10 (34) ◽  
Author(s):  
F. D. MEDINA ◽  
W. B. DANIELS
Keyword(s):  
Raman Spectrum ◽  
Phase Iii ◽  
Solid Methane

Raman spectrum of phase III of solid CH4 in the lattice and intramolecular regions

1979 ◽  
Vol 70 (6) ◽  
pp. 2688-2694 ◽  
Author(s):  
F. D. Medina ◽  
W. B. Daniels
Keyword(s):  
Raman Spectrum ◽  
Phase Iii

Raman spectrum of Na2SO4 (phase III)

1990 ◽  
Vol 74 (2) ◽  
pp. 109-113 ◽  
Author(s):  
Byoung-Koo Choi ◽  
H.J. Labbé ◽  
D.J. Lockwood
Keyword(s):  
Raman Spectrum ◽  
Phase Iii

scholarly journals Phase III of solid methane: The orientational potential and rotational tunneling

2008 ◽  
Vol 128 (3) ◽  
pp. 034503 ◽  
Author(s):  
Alfred Hüller ◽  
Michael Prager ◽  
Werner Press ◽  
Tilo Seydel
Keyword(s):  
Phase Iii ◽  
Solid Methane

RTS,S/AS01, a vaccine targeting pre-erythrocytic stages of Plasmodium falciparum

2017 ◽  
Vol 1 (6) ◽  
pp. 533-537
Author(s):  
Lorenz von Seidlein ◽  
Borimas Hanboonkunupakarn ◽  
Podjanee Jittmala ◽  
Sasithon Pukrittayakamee
Keyword(s):  
Protective Efficacy ◽  
Age Groups ◽  
Sub Saharan Africa ◽  
Phase Iii ◽  
European Medicines Agency ◽  
Older Children ◽  
Pivotal Phase ◽  
Malaria Epidemiology ◽  
Maximum Benefit ◽  
Sub Saharan

RTS,S/AS01 is the most advanced vaccine to prevent malaria. It is safe and moderately effective. A large pivotal phase III trial in over 15 000 young children in sub-Saharan Africa completed in 2014 showed that the vaccine could protect around one-third of children (aged 5–17 months) and one-fourth of infants (aged 6–12 weeks) from uncomplicated falciparum malaria. The European Medicines Agency approved licensing and programmatic roll-out of the RTSS vaccine in malaria endemic countries in sub-Saharan Africa. WHO is planning further studies in a large Malaria Vaccine Implementation Programme, in more than 400 000 young African children. With the changing malaria epidemiology in Africa resulting in older children at risk, alternative modes of employment are under evaluation, for example the use of RTS,S/AS01 in older children as part of seasonal malaria prophylaxis. Another strategy is combining mass drug administrations with mass vaccine campaigns for all age groups in regional malaria elimination campaigns. A phase II trial is ongoing to evaluate the safety and immunogenicity of the RTSS in combination with antimalarial drugs in Thailand. Such novel approaches aim to extract the maximum benefit from the well-documented, short-lasting protective efficacy of RTS,S/AS01.

Rome I versus Rome II; Overlap in patients enrolled in tegaserod phase III clinical trials for irritable bowel syndrome (IBS)

2001 ◽  
Vol 120 (5) ◽  
pp. A284-A284
Author(s):  
B NAULT ◽  
S SUE ◽  
J HEGGLAND ◽  
S GOHARI ◽  
G LIGOZIO ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Irritable Bowel Syndrome ◽  
Phase Iii ◽  
Phase Iii Clinical Trials ◽  
Irritable Bowel ◽  
Rome I

Phase III Study Makes Case for IV Chemoradiation

2007 ◽  
Vol 38 (1) ◽  
pp. 46-47
Author(s):  
BRUCE WILSON
Keyword(s):  
Phase Iii ◽  
Phase Iii Study
Sign in / Sign up

Export Citation Format

Share Document